

Greenwich LifeSciences

Investor Presentation
September 2020

Filed pursuant to Rule 433 of the Securities Act of 1933
Issuer Free Writing Prospectus dated September 22, 2020
Relating to the Preliminary Prospectus dated September 8, 2020
Registration Statement File No. 333-238829



Important Notices and Disclaimers

Greenwich LifeSciences ("we" or "us") has filed a registration statement (including a preliminary prospectus) (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") on Form S-1/A (SEC File No. 333-238829) for the offering to which this presentation relates. Such registration statement has not yet become effective. Shares of our common stock may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. Before you invest, you should read the preliminary prospectus and other documents we file with the SEC for more complete information about our company and this offering. You should read the prospectus in the Registration Statement and other documents that we have filed with the SEC for more complete information about us. You may access these documents for free by visiting EDGAR on the SEC web site at www.sec.gov or by contacting Aegis Capital Corp, 810 7th Avenue, 18th Floor, New York, NY 10019, ATTN: Syndicate Department, e-mail syndicate@aegiscap.com, (212) 813-1010.


This presentation contains "forward-looking statements" within the meaning of the federal securities laws that involve risks and uncertainties, many of which are beyond our control. Our actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Registration Statement. Forward-looking statements relate to matters such as our industry, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, financial condition, liquidity, capital resources, cash flows, results of operations and other financial and operating information. When used in this presentation, the words "will," "may," "believe," "anticipate," "intend," "estimate," "expect," "should," "project," "plan," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.

The forward-looking statements contained in this presentation are based on historical performance and management's current plans, estimates and expectations in light of information currently available to it and are subject to uncertainty and changes in circumstances. There can be no assurance that future developments affecting us will be those that we have anticipated. Actual results may differ materially from these expectations due to the factors, risks and uncertainties described in the Registration Statement, changes in global, regional or local political, economic, business, competitive, market, regulatory and other factors described in the "Risk Factors" section of the Registration Statement, many of which are beyond our control. Should one or more of these risks or uncertainties materialize or should any of our assumptions prove to be incorrect, our actual results may vary in material respects from what we may have expressed or implied by these forward-looking statements. We caution that you should not place undue reliance on any of our forward-looking statements. Any forward-looking statement made by us in this presentation speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable securities laws.



Offering Details


ISSUER	Greenwich LifeSciences, Inc.
PROPOSED TICKER/EXCHANGE	GLSI / NASDAQ Capital Markets
OFFERING TYPE	IPO
GROSS PROCEEDS	\$7,880,437 (15% over-allotment option)
USE OF PROCEEDS	(i) Complete manufacturing of product candidate GP2 (ii) Enroll and treat the first 50 to 100 patients in the Phase III clinical trial (iii) Working capital and other general corporate purposes



About Us

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy, to prevent breast cancer recurrences in patients who have previously undergone surgery

- We have an exclusive worldwide license agreement with The Henry M. Jackson Foundation (HJF), the licensing arm of the U.S. military, for our lead breast cancer drug GP2
- In a Phase IIb clinical trial of HER2/*neu* high level expressor patients completed in 2018, no recurrences were observed after median 5 years of follow-up, if the patient received the 6 primary intradermal injections over the first 6 months (statistically significant, $p=0.0338$)
- Over \$20M in private capital and grants have been invested in our lead breast cancer drug



GP2: A Breakthrough Targeted Immunotherapy

Breast cancer and other solid tumors with an elevated expression of HER2/*neu* protein are highly aggressive with an increased disease recurrence and worse prognosis

- HER2/*neu* is expressed in a variety of common cancers, including 75% of breast cancers at low, intermediate, and high levels
- GP2 immunotherapy elicits a targeted immune response against HER2/*neu* expressing cancers
- In the Phase IIb clinical trial, GP2 immunotherapy produced a potent immune response and a well tolerated safety profile

Substantial Unmet Need

Following breast cancer surgery, a HER2/*neu* high level expressor patient receives Herceptin in the first year, with the hope that their breast cancer will not recur, with the odds of recurrence slowly decreasing over the first 5 years after surgery

- Herceptin has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting
- Kadcylla has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting


We believe that GP2 may be used to address the 50% of recurring patients who do not respond to either of Genentech's FDA approved drugs Herceptin or Kadcylla

The Potential Market for GP2 is Large

1 in 8 U.S. women (12.4%) will develop invasive breast cancer over her lifetime, with 266k new breast cancer patients per year in 2018

- GP2's target market is 6-30% of available breast cancer market or up to 2.4x that of Herceptin in adjuvant setting
 - Herceptin's estimated global revenue in 2019 was \$7 billion
- GP2 could be a long-term treatment that treats survivors (3.1 million as of 2018)
- GP2 potential for > \$15,000 per dose pricing, with 11 doses over 3 years in initial indication


GP2 Overview



GP2 is a 9 amino acid transmembrane peptide segment of the HER2/*neu* protein

- Intradermal injections are administered in combination with an FDA-approved immunoadjuvant GM-CSF, following 1st year of Herceptin treatment in Adjuvant Setting
- One dose per month for 6 months followed by 5 booster doses every 6 months = 11 doses over 3 years

Mechanism of Action: 4 primary steps, followed by a secondary epitope spreading & broader immune response



Compelling Phase IIb Clinical Data

GP2 displayed efficacy in a Phase IIb clinical trial of 180 patients led by MD Anderson Cancer Center

- After median 5 years of follow-up, there were 0% cancer recurrences in HER2/*neu* high level expressor patients when fully vaccinated versus 11% placebo recurrence rate (96 patients, $p=0.0338$)
- In the Phase IIb and three Phase I clinical trials there were no reported serious adverse events related to GP2 treatment (138 patients)
- Combining Herceptin in year 1 and GP2 in years 2-4 may lower breast cancer recurrences
- In the initial GP2 indication, approximately 17,000 new patients could be treated per year in the US, saving up to 1,500 to 2,000 lives per year

Upcoming Phase III Clinical Trial

We are planning to launch a Phase III clinical trial in late 2020 or early 2021, using a similar treatment regime as the Phase IIb clinical trial

- The manufacturing plan and the Phase III trial protocol have been reviewed by the FDA and final revisions to the Phase III trial protocol are underway
- Manufacturing of the GP2 active ingredient for the Phase III trial is complete and we are currently in the process of finalizing our engagement of clinical research organizations for the Phase III clinical trial
- Enrollment period of up to 2 years with primary endpoint to compare recurrence rate of GP2-treated patients vs. placebo at median 2, 3, 4 & 5-years follow-up using standard of care

Corporate Strategy and Pipeline

Our corporate strategy includes advancing GP2 into a Phase III clinical trial in the U.S. with favorable regulatory designations and pursuing a European and global clinical trial strategy to support GP2 registration outside of the U.S.

- We are considering various options to fund the Phase III clinical trial including financing and/or strategic transactions
- Our strategy also includes, among other things, building a commercialization team, pursuing additional funding after this offering, and pursuing strategic collaborations to support the future global marketing and sales of GP2
- A long term global and regional licensing process has been initiated and will continue as the Phase III trial commences
- We are developing follow-on indications for GP2 by designing and planning additional clinical trials to expand the breast cancer patient population and to pursue additional HER2/*neu*-expressing cancers



Capitalization *(as of 6/30/20)*

COMMON SHARES	8,613,190
SERIES A, B, C & D PREFERRED SHARES	1,980,365
WARRANTS AND OPTIONS	0
FULLY DILUTED SHARES	10,593,555
INSIDER OWNERSHIP	80.6%

Seasoned Management Team

The management team has substantial experience in commercializing biotech products, and maintains a controlling interest in GLS, facilitating rapid and decisive decision-making

- David McWilliams, MBA – Chairman, Board
 - 40 years of start-up / CEO experience
 - CEO of 2 private and 3 public biotech companies
- Snehal Patel, MS, MBA – CEO, Board
 - 30 years of biopharma / Wall Street experience
 - Large pharma operations / management experience
- Joe Daugherty, M.D. – CMO, Board
 - 35+ years of biopharma experience
 - Assisted over 20 public and private companies
- Jaye Thompson, Ph.D. – VP Clinical & Regulatory
 - 30 years of active involvement in over 200 clinical trials for drugs, biologics and devices
 - Founder of multiple CROs
- Eric Rothe, MBA – Board
 - Founder of GLS
- Ken Hallock, MBA – Board



Investment Highlights

- Investment opportunity initially focusing on a breakthrough targeted immunotherapy for 6% to 30% of breast cancer market
 - GP2 may be used to address the 50% of recurring patients who do not respond to existing treatments
- GP2 has demonstrated the ability to dramatically effect breast cancer recurrences
 - GP2 Phase IIb resulted in no breast cancer recurrences
- Planning to launch a Phase III clinical trial of GP2 in late 2020 or early 2021
- Significant private capital and grants have been invested in GP2
- Seasoned management team with Big Pharma experience